cardiovascular
Study finds lorcaserin offers sustained weight loss without higher rate of cardiovascular events
A weight loss drug, lorcaserin — currently available in the US, has been found to offer sustained weight loss in patients without a higher rate of cardiovascular events when compared with placebo in a recently published study. more
Correlating Viscosity and Particle Size Parameters determined by Small Angle X-Ray Scattering Studies of concentrated MAb Solutions
Monoclonal antibodies (MAb) solutions are a major class of biopharmaceuticals with various applications. They are important for treating diseases such as cancer, inflammation, allergies, infectious diseases and cardiovascular diseases. more
Study shows monoclonal antibody is effective at reducing cardiovascular risk
Primary data from the CANTOS Phase III trial (sponsored by Novartis) has revealed that a treatment that targets inflammation reduces the risk of cardiovascular disease. more
Heartbroken? Study raises concerns over certainty of efficacy based on biomarkers
A study from researchers at Yale School of Medicine, evaluating cardiovascular trials with primary surrogate endpoints from the past 20 years, have found a disconnect between these trials and clinical outcomes. more
Mind over matter: Side effects are a result of expectations
A recent study, published in the Lancet, suggests that common side effects of statins, namely muscle pain and weakness, are not directly a result of the drugs but more because of patients’ negative expectations. more
Nemera participates in project Cupido
Nemera is contributing to the EU-funded project Cardio Ultraefficient nanoParticles for Inhalation of Drug prOducts (Cupido), which is aimed at applying nanotechnologies to the cardiovascular field. more
Merck receives complete response letter from FDA
The FDA has issued a complete response letter denying Merck’s application to include cardiovascular information on its drug labels for its diabetes drugs, Januvia and Janumet. more
Ibuprofen linked to increased risk of cardiac arrest
A recent study has linked the use of ibuprofen with increased cardiovascular risk. more
Chocolate pill could help cut heart disease risk
A new pill made entirely out of chocolate has been shown to help cut the risk of heart attacks, strokes and dementia. more
Sanifit appoints medical officer and announces new US subsidiary
Laboratoris Sanifit has appointed Dr Preston S. Klassen, MD, MHS as its chief medical officer and announced the launch of its US Subsidiary, based in San Diego, USA. more
Temporary programme grants French children early access to heart medication
Martindale Pharma’s Noyada, a medication that targets heart conditions in children, has been approved for early access in France due to an ATU de’ Cohorte (Temporary Authositaion for Use) programme more
Enrollment completed for acute coronary syndrome drug trial
Sanofi and Regeneron Pharmaceuticals have completed enrollment in the global phase three, Odyssey Outcomes trial for patients suffering from acute coronary syndrome (ACS) more
Making heart disease and cancer drugs affordable in Kenya
Novartis Access has launched in in Kenya. It will be the first country to benefit from a portfolio of 15 affordable medicines to treat cardiovascular diseases, diabetes, respiratory illnesses, and breast cancer more
ELC Group expands into product development
Regulatory affairs services provider ELC Group is expanding into the pharmaceutical development market with the creation of an extensive product portfolio targeting a range of therapeutic areas. more
